

# Exhibit B



PTO/ISS/065 (02-03)  
 Approved for use through 04/30/2003. OMB 0891-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.  
 Instructions for form 1448/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of 4

| Complete if Known      |                 |
|------------------------|-----------------|
| Application Number     | 10/850,385      |
| Filing Date            | August 28, 2003 |
| First Named Inventor   | WEI, et al.     |
| Art Unit               |                 |
| Examiner Name          |                 |
| Attorney Docket Number | 782-A-PCT-US    |

## **OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
| 18                 | 23                    | CAO Hongpeng, JAO Balzhen, Effect of Anti-HBV of 6 Drugs include Lamivudine. Natl Med J China, 2001,81(18):1004-1007  |                |
|                    | 24                    | FEI Junhua, QIN Laiyin, FAN Guilin, et al. Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon T and Lamivudine. Shandong Medical Journal, 1999,39(11): 3-4   |                |
|                    | 25                    | GAO Yuanfu, LIU Guanglin, XIA Zhongkun, et al. Treatment of hepatitis virus-related peridial nephritis with IFN-γ. Academic Journal of Jinlin Hospital, 1999,12(1):24-26  |                |
|                    | 26                    | LEI Binjun, LIU Yuhang, QIU Yangliu, et al. Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon-2. Chinese Journal of Practical Internal Medicine, 1995,15(3):155-157   |                |
|                    | 27                    | LANG Zhanwei, PAN Hongfei, XU Dejun, et al. Observation on Serology and Histology of Patients with Chronic Hepatitis B after Interferon Treatment. Chin J Infect Dis., 2002,20(2):97-100  |                |
|                    | 28                    | WANG Xiangye, LI Xuegang. Comparing Effect of Three Drugs on Turning HBeAg to Negative. Qianwei Medical Journal, 1994,11(4):197-198   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |

|                    |  |                 |         |
|--------------------|--|-----------------|---------|
| Examiner Signature |  | Date Considered | 8/12/05 |
|--------------------|--|-----------------|---------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.